SCHEMBL20540428

SCHEMBL20540428

Cn1ncc(C(N)=O)c1NC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
POLB P06746 1/20 0.50
PDE4B Q07343 3/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
RIPK2 O43353 1/20 0.38
PDE4A P27815 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SIRT3 Q9NTG7 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NNMT P40261 1/20 0.36
TLR8 Q9NR97 1/20 0.35
AHR P35869 1/20 0.35
TYK2 P29597 1/20 0.35
LPAR1 Q92633 1/20 0.35
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15998476 0.82 ALDH1A1 (0.46) ALDH1A1POLBPDE4BNPC1RAB9A
SCHEMBL18343692 0.81 ALDH1A1 (0.46) ALDH1A1POLBPDE4BNPC1RAB9A
SCHEMBL20539629 0.79 MEN1 (0.38) ALDH1A1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL20540560 0.79 ALDH1A1 (0.45) ALDH1A1POLBRAB9ATYK2LPAR1
SCHEMBL28058459 0.78 MEN1 (0.40) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL12258916 0.78 ALDH1A1 (0.43) ALDH1A1POLBPDE4BRIPK2TYK2
SCHEMBL20540314 0.77 MEN1 (0.39) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL18145266 0.76 ALDH1A1 (0.46) ALDH1A1POLBPDE4BNPC1RAB9A
SCHEMBL6397435 0.76 SMN1; SMN2 (0.49) ALDH1A1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL3772649 0.75 MEN1 (0.59) POLBNPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351533-B2 Process for the preparation of carbamoylamino pyrazole derivatives SANDOZ AG (CH) 2019-07-16 US disclosed
EP-3313821-B1 PROCESS FOR THE PREPARATION OF CARBAMOYLAMINO PYRAZOLE DERIVATIVES SANDOZ AG (CH) 2019-04-10 EP disclosed
US-20180305319-A1 Process for the Preparation of Carbamoylamino Pyrazole Derivatives SANDOZ AG (CH) 2018-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351533-B2 Process for the preparation of carbamoylamino pyrazole derivatives PAICS, PPOX, DDC ALDH1A1 2213/4885POLB 577/4885PDE4B 884/4885
US-20180305319-A1 Process for the Preparation of Carbamoylamino Pyrazole Derivatives PAICS, PPOX, DDC ALDH1A1 2213/4885POLB 577/4885PDE4B 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.